Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Accumulated Expenses: 2010-2024

Historic Accumulated Expenses for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $10.3 million.

  • Altimmune's Accumulated Expenses rose 3.96% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.8 million, marking a year-over-year increase of 3.96%. This contributed to the annual value of $10.3 million for FY2024, which is 1.83% up from last year.
  • Altimmune's Accumulated Expenses amounted to $10.3 million in FY2024, which was up 1.83% from $10.1 million recorded in FY2023.
  • In the past 5 years, Altimmune's Accumulated Expenses ranged from a high of $12.2 million in FY2022 and a low of $10.1 million during FY2023.
  • Moreover, its 3-year median value for Accumulated Expenses was $10.3 million (2024), whereas its average is $10.9 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first spiked by 192.16% in 2020, then fell by 17.77% in 2023.
  • Altimmune's Accumulated Expenses (Yearly) stood at $11.4 million in 2020, then declined by 11.01% to $10.2 million in 2021, then climbed by 20.67% to $12.2 million in 2022, then declined by 17.77% to $10.1 million in 2023, then climbed by 1.83% to $10.3 million in 2024.